J&J Pharma CIO: Healthcare data management will revolutionize her businessDate: Jul 24, 2013
Georgia Papathomas, CIO of Johnson & Johnson Pharmaceuticals, is considering "pre-competitive" collaborations as a piece of her cloud and data analytics strategy. View the second part of this CIO Innovators video shot at the MIT Sloan CIO Symposium in Cambridge, Mass., to find out what that means and about the other technologies she believes will revolutionize her industry. Also, be sure to check out part 1 of our video conversation in which Papathomas discusses how technology helps shape the business strategy at J&J Pharma.
What technology do you think will revolutionize your industry or the way we do business?
Georgia Papathomas: So, cloud, for sure. Anything Software as a Service and Platform as a Service, but of everything, the cloud will revolutionize how we run our operations and how we execute our work.
And then you have data management. There's this whole thing about data management and analytics. In the pharmaceutical area, in particular, you have translational informatics, systems biology, high-performance computing in the research area, and then real-world data and social media. So the whole area of information and data will be a big driver for change.
And then of course you have mobility. And I talked about the Web. I think these are major thrusts of technology that are not necessarily new in terms of technology, but the way they will be implemented will be new. Mobility is not something we discovered today, but how mobility is used in the business will revolutionize how we run our business. And the same thing with the Web. The Web is relatively new, but not very new. But the way that information on the Web will be extracted and will be used will be the real innovation in what's new. So these are platforms and technology that we need to understand. The real value in the business is how we use it.
How you are leveraging big data or managing the vast amount of data at your organization?
Papathomas: Especially when we go into the genomes, there's a tremendous amount of data. And we're looking at multiple options. So, one is, we're building capabilities within the business, within our own company.
More on data analytics
Cracking the big data analytics code
Metadata practices gain momentum
The power of personalized data analytics
We're looking for solutions in the cloud, but we're also looking at what we call pre-competitive collaborations. [That is,] partnering with either national laboratories or different institutions, mostly universities, as well as research laboratories, where we have common interests, and we share some of our analytic tools and some of our expertise, science expertise. And we get to have access to their facilities to do both storage and computing.
So we're looking at the whole spectrum. Because, as you said, the data is enormous. If we were to store everything within the company it would be a very expensive proposition. And we're also looking at the data and making some decisions, business decisions, on what data do you need to store. What do you need to analyze and then can purge? And again what do you own and what do you need to access? And so that is driving what the platforms are and where those platforms should reside for us to be able to access our data and do our analytics.